skip to Main Content
  • This page as PDF

A Conversation on Oncology: Download the Slides and Listen to the Recording

Summary

Ahead of the American Society of Clinical Oncology's annual meeting, Avalere experts discussed the latest trends in policy, reimbursement, and market access reshaping oncology care.

The oncology landscape continues to see significant changes as public focus on costs is amplified by drug pricing reforms, providers take on more financial risk, and clinical advancements outpace existing regulatory and reimbursement mechanisms. Provider participation in initiatives such as the Oncology Care Model (OCM) has spurred transformation in oncology care necessitating life science companies to seek new ways to demonstrate value. It is critical to understand how implementation of new reforms and initiatives could impact providers and patients from an access, quality, and affordability perspective.

On May 21, Avalere experts unpacked the complex dynamics stakeholders must consider, spanning policy, market access and reimbursement, and regulatory implications. Meet with us at the annual meeting of the American Society of Clinical Oncology to continue the conversation.

Key Topics

  • Impact of drug pricing policy proposals
  • Evolution of the OCM
  • Reimbursement approaches to novel therapies (e.g., CAR-T)
  • Evidence Generation and FDAMA 114 Opportunities
  • Differential pricing for combination and multi-indication regimens

Panelists

Moderator
Dana Macher , Practice Director, Commercialization & Regulatory Strategy

Dana Macher leads the Commercialization & Regulatory Practice.

Speaker
Lance Grady , Managing Director, Commercialization & Regulatory Strategy

Lance Grady devises commercialization strategies focused on value, access, and reimbursement.

Speaker
Richard Kane , Associate Principal, Policy Analytics

Richard Kane provides data-driven analysis and economic insights for clients across multiple sectors.

Speaker
Milena Sullivan , Principal, Policy

Milena Sullivan advises life sciences clients on the impact of the evolving healthcare policy landscape on their commercial, access, and advocacy priorities.

From beginning to end, our team synergy
produces measurable results. Let's work together.
Back To Top